Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics (NasdaqGS: ZVRA) granted stock options to purchase an aggregate 92,200 common shares to four new employees under its 2023 Employment Inducement Award Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zevra Therapeutics (NasdaqGS: ZVRA) granted stock options to purchase an aggregate 92,200 common shares to four new employees under its 2023 Employment Inducement Award Plan. The options vest over four years, starting with 25% after one year, in accordance with Nasdaq Rule 5635(c)(4).
Details
News Market Reaction – ZVRA
On Aug 24, the first trading day after this news, ZVRA closed 1.85% below the previous close.
Data tracked by StockTitan Argus for the Aug 24 session.
Key Figures
- Inducement shares
- 92,200 shares
- Options granted to four new employees
- Recipients
- 4 employees
- New employees receiving inducement awards
- Vesting period
- 4 years
- Each inducement award
- Initial vesting
- 25%
- On the first anniversary of the employee's start date
Historical Context
-
Revenue growth, profitability, and cash balance accompanied the quarterly report.
-
Conference presentation scheduling preceded a positive price reaction without reported operating or clinical results.
-
Four-year real-world MIPLYFFA data publication preceded a positive price reaction.
-
Negative CHMP opinion on European arimoclomol application preceded a sharp decline.
-
Results-call scheduling preceded a negative price reaction without reported financial results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
inducement awards financial
nasdaq rule 5635(c)(4) regulatory
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company’s common stock (the “Inducement Awards”) to four new employees pursuant to the Company’s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with
Each Inducement Award was approved by the Company’s Compensation Committee and granted as an inducement material to the individual entering into employment with Zevra, in accordance with Nasdaq Rule 5635(c)(4).
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding its ability to advance therapies from development to market and to deliver long-term value. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.